| Name | Title | Contact Details |
|---|
VGA Billing Services is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We are a clinical-stage biopharmaceutical company focused on changing the lives of patients living with nonalcoholic steatohepatitis (NASH) and other liver and metabolic disorders. Our teams in the US and Israel are developing highly differentiated medicines that address unmet medical needs based on robust research. Our lead product candidate, BIO89-100, is a novel long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.
G-CON Manufacturing, Inc.`s prefabricated, turnkey cleanroom systems represent a significant transition to forward thinking in pharmaceutical and biopharmaceutical processing. G-CON Manufacturing, the innovator of autonomous cleanroom PODs, turned the challenges experienced by the biopharmaceutical industry into readily deployable, flexible, mobile and scalable cleanroom solutions. PODs are ideal for multi-product sites, rigorous containment needs, and on demand scaling of production and laboratory space. Building on its first design in 2009, G-CON now has a wide array of cleanroom PODs in their product portfolio to accommodate the increased demand from the pharmaceutical, biopharmaceutical and cell therapeutic industries. Moreover, G-CON`s patent portfolio continues to grow which will effectively preclude imitators from copying G-CON`s initial and more recent innovations. At G-CON, we will continue to evolve and grow with the industry to provide a comprehensive cleanroom solution that truly is flexible, scalable and fast, all for a fair and known price from the time the contract is signed.
Nanosphere is dedicated to enhancing medicine by providing targeted molecular diagnostic tests that can lead to earlier disease detection, optimal patient treatment and improved healthcare economics. Nanosphere’s platform, the Verigene® System, enables clinicians to rapidly identify and treat the bacteria and viruses responsible for some of the most complex, costly and deadly infectious diseases. Headquartered in Northbrook, Illinois, Nanosphere was founded in 1999 based upon technology developed at Northwestern University by Dr. Robert Letsinger and Dr. Chad Mirkin. In 2007, Nanosphere went public (NASDAQ: NSPH), and has remained committed to continued scientific discovery and innovation with more than 175 patents to its name.
The mission of 4D Molecular Therapeutics is to design and develop transformative gene therapy products using our proprietary technology to create novel adeno-associated virus variants to be utilized as treatments for serious unmet medical conditions. Our products are unlocking the full potential of gene therapy to treat, and potentially cure, genetic diseases. A large number of patients and diseases, who previously were not treatable by gene therapy, will be addressable by 4D products. 4D has one of the deepest and most diverse product pipelines in the gene therapy field. Adeno-associated virus (AAV) vectors have emerged as a favored delivery vehicle for gene therapy in the human body. They can deliver the genes for therapeutic proteins to accessible tissues in the body and are generally considered safe. Several AAV gene therapy products are in late-stage clinical development, and one product is approved in the EU (Glybera, Uniqure). However, these first-generation AAV vectors have limited utility for the majority of diseases. Many of these common AAV were discovered as laboratory contaminants and monkey infections, for example; they have not been customized as targeted medicines. In contrast, 4D customized AAV vectors, and the products made from them, are designed to unlock the full potential of gene therapy. Through 4D`s Therapeutic Vector Evolution, we are able to create customized vectors solutions to overcome the hurdles identified with first-generation AAV vectors. 4D is creating the ultimate gene therapy products to cure genetic diseases using new customized delivery vehicles (vectors) to shuttle genes into the cells in any organ in the body. This 4D “library” of vectors will soon include several for the liver, several for the brain, several for the heart, the eye, muscle, and so on. Doctors will be able to hand pick a vector for any patient based on the organ that is diseased.